home / stock / ktta / ktta news


KTTA News and Press, Pasithea Therapeutics Corp. From 06/29/23

Stock Information

Company Name: Pasithea Therapeutics Corp.
Stock Symbol: KTTA
Market: NASDAQ
Website: pasithea.com

Menu

KTTA KTTA Quote KTTA Short KTTA News KTTA Articles KTTA Message Board
Get KTTA Alerts

News, Short Squeeze, Breakout and More Instantly...

KTTA - Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a licensed producer of compounds for medicinal products, today announced that it had reaffirmed its proposal to Pasithea Therapeutics...

KTTA - Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004

PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous sys...

KTTA - Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

PALO ALTO, Calif. and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous sys...

KTTA - Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a licensed producer of compounds for medicinal products, today announced that it sent a proposal to Pasithea Therapeutics Corp. (...

KTTA - Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

2023-06-01 08:45:42 ET Palm Beach, FL – June 1, 2023 – FinancialNewsMedia.com News Commentary – Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumor...

KTTA - Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous sys...

KTTA - Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervou...

KTTA - Pasithea Therapeutics files for $15M mixed shelf offering

2023-03-30 18:46:36 ET Pasithea Therapeutics ( KTTA ) on Thursday filed for a mixed shelf offering of up to $15M. The offering may include common stock, preferred stock, warrants, subscription rights and units. The filing does not necessarily indicate that a sale has ...

KTTA - Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA ) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Ner...

KTTA - Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS...

Previous 10 Next 10